The client is a Top 10 global pharmaceutical company with a diverse portfolio spanning more than 15 brands across multiple therapeutic areas. With a strong commercial footprint and commitment to scientific innovation, the organization manages a highly complex promotional review process, handling more than 2,000 Medical, Legal, and Regulatory (MLR) jobs every quarter.
Despite its scale and sophistication, the organization faced several roadblocks in optimizing its MLR review process:
Slow Content Turnaround: The current MLR workflow struggled to push content through the review cycle efficiently, leading to delays in content approval and extended time to market.
Lack of Benchmarking Insights: Limited access to industry benchmarks and peer comparisons made it difficult for teams to evaluate performance objectively or identify areas for improvement.
No Clear Prioritization Framework: The absence of a structured framework to prioritize MLR jobs hindered the ability to build a clear, actionable execution plan—leading to resource bottlenecks and inefficiencies in managing workload across teams.
Indegene leveraged its proprietary MLR Maturity Benchmark framework to assess the end-to-end MLR process and identify key inefficiencies. The team:
Identified four key focus areas for optimization:
Agency management
Process and field data management
Metrics-driven governance
Customized automation accelerators
Developed 10+ strategic recommendations with clear prioritization:
Quick wins for immediate efficiency gains
Long-term solutions for sustainable impact
Defined a tailored 2-year roadmap and implementation plan to:
Accelerate content turnaround times
Enhance cross-functional alignment
Build a future-ready, scalable MLR process
After one year of implementing Indegene’s recommendations, the client achieved significant improvements across their MLR process, enhancing both efficiency and quality while enabling scalability. Additionally, the client gained better visibility into MLR performance, empowering data-driven decision-making.